Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

In the phase 2/3 DEVOTE study, a higher dose of nusinersen met its primary end point at 6 months, achieving a statistically significant improvement in motor function among treatment-naïve symptomatic infants with SMA.

FDA Accepts sNDA for Higher Dosing Regimen of Nusinersen for Spinal Muscular Atrophy

Videos

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program provided commentary on patient selection and personalized treatment approaches when using neuromodulation devices for Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

Personalizing Neuromodulation and Tailoring Approaches for Lennox-Gastaut Syndrome: Depobam Samanta, MD, MS, FAAP, FAES

Leah Blank, MD, an assistant professor of neurology, population health, science, and policy at the Icahn School of Medicine provided commentary on some of the experience and positive movement from the 2024 American Epilepsy Society Annual Meeting.

Insights From AES 2024: Advancements and Challenges in Epilepsy Care

At ECTRIMS 2024, the postdoctoral research assistant at Charité University Berlin discussed how the updated diagnostic criteria aim to address gaps in diagnosing and treating overlapping autoimmune conditions. [WATCH TIME: 4 minutes]

Implications of New Multiple Sclerosis Criteria on Overlapping Autoimmune Conditions: Joseph Kuchling, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Professor, department of neurology, NYU Langone Health Center, and codirector, Epilepsy Clinical Trials, NYU Langone, Comprehensive Epilepsy Center; founder/director, Epilepsy Study Consortium.

The professor of neurology at NYU Grossman School of Medicine talked about using responsive neurostimulators to seek shortened drug evaluation timelines and enhance epilepsy treatment.

NeuroVoices: Jacqueline A. French, MD, on Leveraging Neurostimulators to Advance Epilepsy Drug Development

The study highlighted tofersen's potential to slow ALS progression in patients with SOD1 mutations, showing reduced neurofilament levels, functional stabilization, and improved muscle strength, despite mild to moderate adverse events.

Real-World Study Highlights Positive Treatment Benefits of Tofersen on ALS Disease Progression, Function

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AES 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Cure SMA:  Evaluation of SMA in the Era of Telehealth

Cure SMA

SAP Partners

The NeurologyLive Cure Connections series, “Evaluation of Spinal Muscular Atrophy in the Era of Telehealth,” put on in partnership with Cure SMA, features Diana Castro, MD, and Garey H. Noritz, MD, who offer tips and demonstrations for screening and diagnosing SMA via telehealth. Additionally, resources provided by Cure SMA are outlined for families and clinicians who suspect SMA or have a patient diagnosed with SMA.

Diana Castro, MD walks us through a pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Pediatric Neurological Exam to Identify SMA

Garey H. Noritz, MD, walks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy 

Early recognition and referral of a patient with suspected spinal muscular atrophy (SMA) to a neurologist.

Referral of SMA to a Neurologist

Diana Castro, M.D., discusses newborn screening for spinal muscular atrophy (SMA) and suggests how to care for patients after the results are received.  

Newborn Screening for SMA

The signs and symptoms leading a pediatrician to a diagnosis of spinal muscular atrophy (SMA) are discussed.

Signs and Symptoms of SMA

Diana Castro, M.D., stresses the value of the initial in-person neurology visit for evaluation of spinal muscular atrophy (SMA) to ensure a correct diagnosis. The next step in the process would be genetic testing.

Evaluation of Suspected SMA via In-Person and Remote Exam

Discussing the diagnosis of spinal muscular atrophy (SMA) with the family and lining up appointments with the multidisciplinary team to help care for the patient.

Discussing the Diagnosis of SMA With the Family

Several spinal muscular atrophy (SMA) resources are suggested to help physicians and families, including Cure SMA and standard of care guidelines.

SMA Resources for Physicians and Families

Resources are discussed, including the Child Neurology Foundation’s telehealth tip sheet, to help families navigate telehealth.

Telehealth During COVID-19

Experts remind families of the importance of follow-up visits with the multidisciplinary team during COVID-19.

Importance of Follow-Up Visits for SMA Amid COVID-19

Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).

Advice to Community Neurologists Treating SMA

SAP Partner

Clinical

 video series brings together expert clinicians and patients with neurologic diseases and disorders to discuss the landscapes of care, management, and treatment from both perspectives.

Pediatric Neurological Exam to Identify SMA

EP: 1.Pediatric Neurological Exam to Identify SMA

EP: 2.Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

EP: 3.Referral of SMA to a Neurologist

EP: 4.Newborn Screening for SMA

EP: 5.Signs and Symptoms of SMA

EP: 6.Evaluation of Suspected SMA via In-Person and Remote Exam

EP: 7.Discussing the Diagnosis of SMA With the Family

EP: 8.SMA Resources for Physicians and Families

EP: 9.Telehealth During COVID-19

EP: 10.Importance of Follow-Up Visits for SMA Amid COVID-19

EP: 11.Advice to Community Neurologists Treating SMA